a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

计划入组 140 人 · 首次发布于 2023 年 12 月 12 日

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

计划入组 51 人 · 首次发布于 2019 年 9 月 30 日

IN10018 in Combination With Dalpiciclib for Progressive Meningiomas

计划入组 24 人 · 首次发布于 2026 年 6 月 17 日

Ifebemtinib

C₂₈H₂₈F₄N₆O₄

[14C] Ifebemtinib (InxMed)

IN30718

Ifebemtinib Plus Garsorasib Shows 82% ORR and 22-Month PFS in First-Line KRAS G12C-Mutant NSCLC

InxMed's Ifebemtinib Receives Breakthrough Therapy Designation for NSCLC with KRAS G12C Mutation

InxMed Reports Breakthrough Results for Ifebemtinib-Garsorasib Combination in KRAS G12C-Mutant Cancers at ASCO 2025